NCT05759962View on ClinicalTrials.gov

Phase 1 Study of LQT-1213 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

March 5, 2023

Study Completion Date

March 5, 2023

Conditions
Long QT Syndrome
Interventions
DRUG

LQT-1213

LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

OTHER

Placebo

Matching Placebo

Trial Locations (1)

90630

Altasciences Clinical Los Angeles, Inc., Cypress

All Listed Sponsors
lead

Thryv Therapeutics, Inc.

INDUSTRY